Acalabrutinib Shows Promise for Elderly CLL Patients

At ASH 2024, Dr. Florian Simon shared findings from a trial evaluating acalabrutinib for treating CLL in patients aged 80 and older. The results showed a 93% response rate and significant frailty improvements after six months of treatment, highlighting the drug’s efficacy and safety for older, frail populations while emphasizing tailored approaches for those with cardiac comorbidities.